Social media

Site activation delays cost trials time and trust. ICON’s new whitepaper shows how human-centred strategies accelerate startup and improve site satisfaction. Download now: https://ow.ly/j6RK50XB6ZW

USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-worl...

Do you know the difference between decision trees and random forests? Learn about AI models for SaMDs in our new whitepaper. Download it now to learn best practices for model and data selection. https://ow.ly/nI8g50XAzbq

For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase...

Attending #ASH25? Stop by booth \#2161 to meet the ICON team and discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research ...

ICON was amongst several leading Irish businesses that participated in the first Ireland-Ukraine Economic Forum: https://lnkd.in/eQmATh-f

The CRA role is evolving—from data checker to strategic partner. ICON’s Helen Yeardley explores how technology is reshaping clinical trial oversight. Read the Applied Clinical Trials article: https://ow.ly/paW350XB6R6

The CRA role is evolving—from data checker to strategic partner. ICON’s Helen Yeardley explores how technology is reshaping clinical trial oversight. Read the Applied Clinical Trials article: https://ow.ly/9nyk50XB6R3

Therapeutic developers can reshape the future of HIV control by creating interventions that are effective despite persistent real-world challenges. Discover what developers need to take into consideration to make a real-...

Because existing HIV therapies are already highly effective when taken as prescribed, traditional trial settings often fail to reveal the added value of emerging approaches. Explore how developers can plan trials that ...

Meet ICON’s experts at #ASH25, booth \#2161 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https:...

Tomorrow, 6 December, is the final day of the SCDM #INDIA25! ICON’s experts have been sharing insights in sessions covering clinical trials and data management, regulatory affairs, biotech and pharma partnerships, real-w...